Study drugs before transplant for myeloma with kidney problems
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether a combination of anti-myeloma medicines given before stem cell transplant works well and is safe for people with multiple myeloma who also have kidney problems. It may help control the myeloma and prepare you for the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and able to sign consent before any study steps.
- Have multiple myeloma confirmed by a bone marrow test (or a plasmacytoma) plus evidence of organ damage, such as kidney problems, anemia, high calcium, or very high bone marrow plasma cells.
- Have “measurable” disease (for example, certain abnormal blood or urine protein levels or abnormal free light chains).
- Be well enough for transplant planning (autologous stem cell transplant eligibility based on the study site) and have performance status 0–2.
- Have kidney problems and fit the study’s renal-impaired group rules, and for this trial you can have had limited prior myeloma treatment only in the past up to 4 weeks (including dexamethasone, bortezomib, and/or cyclophosphamide) for urgent symptoms.
- Use effective birth control (or practice true abstinence) during treatment and for 16 weeks after the last dose; avoid pregnancy/breastfeeding during this time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
This trial tests a specific chemotherapy combination (thiotepa and melphalan) given before a stem cell transplant to treat multiple myeloma. The study compares this approach to help doctors understand if it improves outcomes for patients whose myeloma hasn't fully responded to initial treatment.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This trial studies whether a structured exercise program before an autologous (your own cells) stem cell transplant can improve health and fitness in people with multiple myeloma. The goal is to safely prepare your body for transplant, and the study includes fitness testing and ongoing exercise training.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.